Inclusion Criteria:

• Phenotypic familial adenomatous polyposis (FAP) with disease involvement of the colorectum by either genetic or clinical diagnosis: Adenomatous polyposis coli (APC) germline mutation with or without family history, or with greater than (>)100 adenomas in large intestine and a family history of FAP, attenuated FAP is allowed. FAP phenotype post colectomy for polyposis with a family history of FAP may be allowed.
• Post-colectomy or subtotal colectomy.
• Polyps with a sum of diameters greater than or equal to (≥)10 millimeter (mm) in the rectum or pouch on biopsy at screening.
• A woman of childbearing potential must agree not to get pregnant during the study and at least 12 weeks after the last dose of study administration.
• A woman must agree not to breast feed or donate eggs (ova, oocytes) during the study and for a period of 12 weeks after the last administration of study drug.

Exclusion Criteria:

• Prior use of any biologic therapy targeting interleukin (IL)-12/23, IL-17, or IL-23 receptor.
• Use of non-steroidal anti-inflammatory drugs other than aspirin during the study. The use 100 milligram (mg) of aspirin a day or 700 mg of aspirin per week is allowed.
• Treatment with other FAP-directed drug therapy (including NSAID [Nonsteroidal anti-inflammatory drug] drugs), unless completes a 4-week washout period prior to randomization.
• High grade dysplasia or cancer on biopsy at screening in GI tract (including stomach, duodenum, and colon/rectum/pouch).
• Subjects with polyps that are > 2 cm that have not been excised at screening or with polyps that are 1 to 2 cm with evidence of high-grade dysplasia upon biopsy unless excised will be excluded from the study.